טוען...
Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
BACKGROUND: Advanced prostate cancer is currently treated with androgen deprivation therapy (ADT). ADT initially results in tumor regression, however, all patients eventually relapse with castration-resistant prostate cancer. New approaches to delay the progression of prostate cancer to castration r...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3319476/ https://ncbi.nlm.nih.gov/pubmed/22161776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22458 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|